Disintegrin variants that bind specifically to one or more of α5β1 and αv integrins, such as ανβ1, ανβ3, ανβ5, ανβ6 and ανβ8, but with reduced binding activity to αIIbβ3, are described. Also described are uses of the disintegrin variants for the treatment or prevention of a disease associated with an αv integrin or an α5β1 integrin.